CA3254271A1 - Polytherapies for Breast Cancer - Google Patents
Polytherapies for Breast CancerInfo
- Publication number
- CA3254271A1 CA3254271A1 CA3254271A CA3254271A CA3254271A1 CA 3254271 A1 CA3254271 A1 CA 3254271A1 CA 3254271 A CA3254271 A CA 3254271A CA 3254271 A CA3254271 A CA 3254271A CA 3254271 A1 CA3254271 A1 CA 3254271A1
- Authority
- CA
- Canada
- Prior art keywords
- breast cancer
- combination therapies
- therapies
- combination
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269326P | 2022-03-14 | 2022-03-14 | |
| US63/269,326 | 2022-03-14 | ||
| PCT/US2023/064143 WO2023178019A1 (en) | 2022-03-14 | 2023-03-10 | Combination therapies for breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254271A1 true CA3254271A1 (en) | 2023-09-21 |
Family
ID=85937455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254271A Pending CA3254271A1 (en) | 2022-03-14 | 2023-03-10 | Polytherapies for Breast Cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250177364A1 (https=) |
| EP (1) | EP4493180A1 (https=) |
| JP (1) | JP2025509510A (https=) |
| KR (1) | KR20240163084A (https=) |
| CN (1) | CN118843461A (https=) |
| AU (1) | AU2023234511A1 (https=) |
| CA (1) | CA3254271A1 (https=) |
| IL (1) | IL315153A (https=) |
| MX (1) | MX2024011183A (https=) |
| TW (1) | TW202400230A (https=) |
| WO (1) | WO2023178019A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2437300A (en) | 1999-01-15 | 2000-08-01 | Infineum International Ltd | Improved fuel compositions |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| TWI800827B (zh) * | 2020-05-12 | 2023-05-01 | 美商建南德克公司 | 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌 |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| MX2023000622A (es) | 2020-07-14 | 2023-02-22 | Genentech Inc | Ensayos para combinaciones de dosis fija. |
-
2023
- 2023-03-10 IL IL315153A patent/IL315153A/en unknown
- 2023-03-10 CN CN202380026682.0A patent/CN118843461A/zh active Pending
- 2023-03-10 MX MX2024011183A patent/MX2024011183A/es unknown
- 2023-03-10 JP JP2024554636A patent/JP2025509510A/ja active Pending
- 2023-03-10 AU AU2023234511A patent/AU2023234511A1/en active Pending
- 2023-03-10 KR KR1020247031992A patent/KR20240163084A/ko active Pending
- 2023-03-10 US US18/844,654 patent/US20250177364A1/en active Pending
- 2023-03-10 EP EP23715700.3A patent/EP4493180A1/en active Pending
- 2023-03-10 CA CA3254271A patent/CA3254271A1/en active Pending
- 2023-03-10 TW TW112109034A patent/TW202400230A/zh unknown
- 2023-03-10 WO PCT/US2023/064143 patent/WO2023178019A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025509510A (ja) | 2025-04-11 |
| KR20240163084A (ko) | 2024-11-18 |
| EP4493180A1 (en) | 2025-01-22 |
| AU2023234511A1 (en) | 2024-09-12 |
| IL315153A (en) | 2024-10-01 |
| CN118843461A (zh) | 2024-10-25 |
| TW202400230A (zh) | 2024-01-01 |
| US20250177364A1 (en) | 2025-06-05 |
| MX2024011183A (es) | 2024-09-18 |
| WO2023178019A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3254271A1 (en) | Polytherapies for Breast Cancer | |
| EP3836909A4 (en) | BIOMARKERS FOR CANCER THERAPY | |
| EP4291902A4 (en) | BIOMARKERS FOR CANCER TREATMENT | |
| EP4330256A4 (en) | PYRIMIDINYLAMINOBENZOLES FOR THE TREATMENT OF LUNG CANCER | |
| GB202208347D0 (en) | Targets for cancer therapy | |
| EP4045009A4 (en) | METHOD FOR TREATING BREAST CANCER | |
| AU2023409221A1 (en) | Combination therapy for lung cancer | |
| HK40121815A (en) | Combination therapies for breast cancer | |
| EP4139508A4 (en) | COMPREHENSIVE POLYGENIC RISK PREDICTION FOR BREAST CANCER | |
| EP4226945A4 (en) | MEDICINES FOR THE TREATMENT OF CANCER | |
| EP3981473A4 (en) | Therapeutic agent for cancer | |
| GB202309496D0 (en) | Cancer therapies | |
| CA3243227A1 (en) | POLYTHERAPY AGAINST CANCER | |
| HK40025336B (en) | Cancer therapies | |
| HK40025336A (en) | Cancer therapies | |
| HK40117032A (en) | Combination therapy for cancer | |
| HK40096988A (en) | Combination therapy for cancer | |
| HK40108212A (en) | Combination therapies for treating cancer | |
| HK40107080A (en) | Combination therapies for treating cancer | |
| HK40088510A (en) | Comprehensive polygenic risk prediction for breast cancer | |
| CA3275995A1 (en) | Combination therapy for lung cancer | |
| CA3306292A1 (en) | Combination therapies for treating cancers | |
| AU2023901714A0 (en) | Combination cancer therapy | |
| HK40101495A (en) | Combination therapy with for46 for cancer | |
| GB202208893D0 (en) | Combination therapy for cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240911 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250213 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250912 |